About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
MARIO
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
April 2020
Prevention of
Pneumocystis
Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
Stephen Barat, Katyna Borroto-Esoda, Alan Ashbaugh, Melanie Cushion
ECCMID 2020
April 2020
CANDIMAD study: a prospective multi-centre laboratory based survey of antifungal resistance in
Candida
spp. causing invasive candidiasis in Madrid
Judith Diaz-Garcia, Aina Mesquida, María Ángeles Meléndez Carmona, Fernando González-Romo, Cuetara Maria Soledad, Nelly Daniela Zurita Cruz, Maria Muñoz Algarra, Maria Del Coral Garcia, Aída Sánchez, Inmaculada Quiles, Maria Teresa Duran-Valle, Carlos Sanchez-Carrillo, Patricia Muñoz, Pilar Escribano, Jesus Guinea Ortega
February 2020
In vitro
Evaluation of Combination of Ibrexafungerp and Azoles against
Aspergillus
spp. Isolated from Lung Transplant Recipients
Vidya Jagadeesan, Eileen Driscoll, Binghua Hao, Stephen Barat, Katyna Borroto-Esoda, Tom Chen, David Angulo, Cornelius J Clancy, M. Hong Nguyen
AAAM 2020
October 2019
Candida auris
is Highly
In Vitro
Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing
Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary and Maiken Cavling Arendrup
TIMM 2019
October 2019
Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against
Candida auris: In Vitro, In Vivo
and Clinical Case Studies of Candidemia
S. Barat, D. Angulo
TIMM 2019
October 2019
Successful Treatment of a Patient with Retroperitoneal Abscess caused by
Candida krusei
with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI study
GR Thompson, David Angulo
TIMM 2019
October 2019
Successful Treatment of a Patient with Retroperitoneal Abscess caused by
Candida krusei
with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study
George R. Thompson III, David Angulo
TIMM 2019
June 2019
Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of
Candida auris
Cutaneous Infection in a Guinea Pig Model
M. Ghannoum, L. Long, C. Hager, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019
Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderua, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ASM Microbe 2019
April 2019
Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
< Prev
Next >
Please ensure Javascript is enabled for purposes of
website accessibility